Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 706-708

  Dardikh, M ^a   Albert, T ^b   Masereeuw, R ^a   Oldenburg, J ^b   Novakova, I ^a   Van Heerde, W L ^a   Verbruggen, B ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

BIOASSAY; BLEEDING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG HALF LIFE; HEMOPHILIA; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LETTER; NIJMEGEN ASSAY; PRIORITY JOURNAL;

ANTIBODIES; BLOOD CHEMICAL ANALYSIS; COAGULANTS; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; INFUSIONS, INTRAVENOUS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84859173395     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04645.x     Document Type: Letter

References (8)

1. Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinolysis 1993; 4: 753-8.
2. Brackmann HH, Gormsen J. Massive factor-VIII infusion in hemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 28: 93.
3. Dimichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 2007; 5(Suppl. 1): 143-50.
4. Dimichele DM, Hay CRM. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.
5. Hay CR, Dimichele DM, on behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
6. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
7. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
8. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S, International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.